Research map: AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group

Back to the article

Papers in this map

  1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel · Hartmut Döhner · 2016 · 5984 citations · Cited by this paper
  2. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab · 2026 · Related
  3. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort · Daniel A. Mulrooney · 2009 · 1181 citations · Cited by this paper
  4. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program · 2026 · Related
  5. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia · Jeffrey E. Lancet · 2018 · 1024 citations · Cited by this paper
  6. Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development · 2026 · Related
  7. Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 · Alan S. Gamis · 2014 · 491 citations · Cited by this paper
  8. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up · 2026 · Related
  9. Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer · Raoul C. Reulen · 2010 · 449 citations · Cited by this paper
  10. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor · 2026 · Related
  11. Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial · Alan K. Burnett · 2013 · 429 citations · Cited by this paper
  12. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer · 2026 · Related
  13. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia · Christian Michel Zwaan · 2015 · 392 citations · Cited by this paper
  14. Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective · 2026 · Related
  15. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy · Paul G. Tardi · 2008 · 361 citations · Cited by this paper
  16. Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743 · 2026 · Related
  17. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML · Jeffrey E. Lancet · 2014 · 340 citations · Cited by this paper
  18. Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? · 2026 · Related
  19. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group · WG Woods · 1996 · 333 citations · Cited by this paper
  20. Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update · 2026 · Related
  21. First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia · Eric Jay Feldman · 2011 · 308 citations · Cited by this paper
  22. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial · Jeffrey E. Lancet · 2021 · 229 citations · Cited by this paper
  23. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia · Todd M. Cooper · 2011 · 201 citations · Cited by this paper
  24. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group · Richard Aplenc · 2020 · 180 citations · Cited by this paper
  25. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study · Seth E. Karol · 2020 · 169 citations · Cited by this paper
  26. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts · Wah-Seng Lim · 2010 · 164 citations · Cited by this paper
  27. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group · Richard Aplenc · 2006 · 135 citations · Cited by this paper
  28. A new genomic framework to categorize pediatric acute myeloid leukemia · Masayuki Umeda · 2024 · 122 citations · Cited by this paper
  29. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort · Edmond Chiche · 2021 · 114 citations · Cited by this paper
  30. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group · Kelly Getz · 2018 · 107 citations · Cited by this paper
  31. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells · Hyun Pyo Kim · 2011 · 86 citations · Cited by this paper
  32. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group · Todd M. Cooper · 2020 · 68 citations · Cited by this paper
  33. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial · Jad Othman · 2023 · 60 citations · Cited by this paper
  34. Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms · Todd M. Cooper · 2023 · 32 citations · Cited by this paper
  35. CREST ‐ UK : Real‐world effectiveness, safety and outpatient delivery of CPX ‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK · Priyanka Mehta · 2024 · 17 citations · Cited by this paper
  36. Outcomes of intensification of induction chemotherapy for children with high‐risk acute myeloid leukemia: A report from the Children's Oncology Group · Caitlin W. Elgarten · 2021 · 14 citations · Cited by this paper
  37. Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service · Alex Legg · 2023 · 11 citations · Cited by this paper
  38. CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial · Shai O. Shimony · 2026 · 8 citations · Cited by this paper
  39. CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial · Steven Knapper · 2025 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)